Total Payments
$1.6M
2024 Payments
$175,436
Companies
71
Transactions
2,217
Medicare Patients
4,942
Medicare Billing
$2.1M
Payment Breakdown by Category
Other$1.2M (73.6%)
Consulting$253,962 (16.1%)
Travel$103,518 (6.6%)
Food & Beverage$35,651 (2.3%)
Research$12,855 (0.8%)
Education$10,701 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 498 | 66.2% |
| Consulting Fee | $253,962 | 104 | 16.1% |
| Honoraria | $118,075 | 52 | 7.5% |
| Travel and Lodging | $103,518 | 475 | 6.6% |
| Food and Beverage | $35,651 | 1,072 | 2.3% |
| Unspecified | $12,855 | 12 | 0.8% |
| Education | $10,701 | 4 | 0.7% |
Payments by Type
General
$1.6M
2,205 transactions
Research
$12,855
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $555,687 | 676 | $0 (2022) |
| ABBVIE INC. | $231,514 | 278 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $133,555 | 100 | $0 (2024) |
| MDD US Operations, LLC | $129,992 | 112 | $0 (2024) |
| Acorda Therapeutics, Inc | $126,956 | 119 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $117,064 | 213 | $0 (2024) |
| US WorldMeds, LLC | $84,694 | 202 | $0 (2020) |
| Adamas Pharmaceuticals, Inc. | $62,193 | 76 | $0 (2021) |
| Kyowa Kirin, Inc. | $41,743 | 45 | $0 (2024) |
| ARBOR PHARMACEUTICALS, INC. | $23,233 | 46 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $175,436 | 254 | ABBVIE INC. ($77,989) |
| 2023 | $230,426 | 255 | ABBVIE INC. ($86,551) |
| 2022 | $185,403 | 201 | ABBVIE INC. ($56,127) |
| 2021 | $258,697 | 247 | Allergan, Inc. ($152,525) |
| 2020 | $207,259 | 251 | Allergan, Inc. ($132,036) |
| 2019 | $236,620 | 415 | Allergan Inc. ($107,349) |
| 2018 | $162,669 | 319 | Allergan Inc. ($70,496) |
| 2017 | $123,672 | 275 | Allergan Inc. ($67,279) |
All Payment Transactions
2,217 individual payment records from CMS Open Payments — Page 1 of 89
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 12/16/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 12/12/2024 | Philips North America LLC | (8874) inCourage (Device) | Food and Beverage | Cash or cash equivalent | $15.63 | General |
| Category: Medical Device | ||||||
| 12/10/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/26/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/10/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $863.96 | General |
| 11/10/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $145.90 | General |
| 11/09/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $361.78 | General |
| 11/09/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $145.90 | General |
| 11/09/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $63.32 | General |
| 11/09/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $17.18 | General |
| 11/07/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | ABBVIE INC. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $17.42 | General |
| Category: NEUROSCIENCE | ||||||
| 11/03/2024 | MDD US Operations, LLC | Apokyn (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: APOMORPHINE HYDROCHLORIDE | ||||||
| 10/31/2024 | Ipsen Innovation | Dysport (Drug) | Consulting Fee | Cash or cash equivalent | $7,560.00 | General |
| Category: Neurology | ||||||
| 10/29/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 10/29/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $9.66 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/16/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,780.00 | General |
| Category: Neurology | ||||||
| 10/16/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Travel and Lodging | In-kind items and services | $39.47 | General |
| Category: Neurology | ||||||
| 10/16/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $11.13 | General |
| Category: Neurology | ||||||
| 10/11/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Education | In-kind items and services | $5,211.00 | General |
| Category: NEUROLOGY | ||||||
| 10/11/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Education | In-kind items and services | $289.50 | General |
| Category: NEUROLOGY | ||||||
| 10/11/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Travel and Lodging | In-kind items and services | $60.00 | General |
| Category: NEUROLOGY | ||||||
| 10/11/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Travel and Lodging | In-kind items and services | $40.20 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | Eli Lilly and Company | $8,871 | 4 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,729 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,027 | 2 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $356.00 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $356.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $355.00 | 1 |
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Pharmaceuticals U.S.A., Inc. | $161.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,159 | 74,805 | $1.7M | $549,571 |
| 2022 | 24 | 1,311 | 74,313 | $1.4M | $583,939 |
| 2021 | 21 | 1,320 | 65,373 | $1.1M | $522,639 |
| 2020 | 21 | 1,152 | 56,728 | $983,710 | $431,527 |
Total Patients
4,942
Total Services
271,219
Medicare Billing
$2.1M
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 3 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 113 | 164 | $41,000 | $22,602 | 55.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 76 | 76 | $26,600 | $13,324 | 50.1% |
| 64612 | Injection of chemical for destruction of nerve muscles on one side of face | Office | 2021 | 36 | 104 | $39,300 | $12,881 | 32.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 101 | 101 | $30,300 | $12,275 | 40.5% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2021 | 85 | 193 | $32,000 | $12,158 | 38.0% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Office | 2021 | 27 | 28 | $22,400 | $10,212 | 45.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 84 | 86 | $21,550 | $9,699 | 45.0% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Office | 2021 | 28 | 29 | $18,850 | $7,919 | 42.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 85 | 92 | $13,800 | $6,741 | 48.9% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 21 | 61 | $24,400 | $6,644 | 27.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 77 | 97 | $8,730 | $5,765 | 66.0% |
| 64644 | Injection of chemical for destruction of nerve muscles on one arm or leg, 5 or more muscles | Office | 2021 | 17 | 42 | $13,900 | $5,645 | 40.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 18 | $6,300 | $2,929 | 46.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 32 | $4,160 | $2,708 | 65.1% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 13 | 24 | $4,200 | $2,045 | 48.7% |
| 64405 | Injection of anesthetic agent and/or steroid into greater occipital nerve of upper neck and back of head | Office | 2021 | 13 | 16 | $7,200 | $1,231 | 17.1% |
| 92250 | Photography of the retina | Office | 2021 | 11 | 11 | $2,200 | $347.93 | 15.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 88 | 46,775 | $467,750 | $215,187 | 46.0% |
| J0586 | Injection, abobotulinumtoxina, 5 units | Office | 2020 | 15 | 7,120 | $85,440 | $45,586 | 53.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 253 | 415 | $93,375 | $31,965 | 34.2% |
| 64616 | Injection of chemical for destruction of nerve muscles on one side of neck excluding voice box accessed through the skin | Office | 2020 | 36 | 100 | $40,000 | $16,756 | 41.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 112 | 114 | $28,500 | $12,795 | 44.9% |
| 64612 | Injection of chemical for destruction of nerve muscles on one side of face | Office | 2020 | 32 | 100 | $35,200 | $12,049 | 34.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 89 | 116 | $29,000 | $11,514 | 39.7% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2020 | 12 | 1,225 | $24,500 | $11,189 | 45.7% |
About Dr. Aaron Ellenbogen, D.O
Dr. Aaron Ellenbogen, D.O is a Neurology healthcare provider based in Farmington Hills, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962472241.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aaron Ellenbogen, D.O has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $175,436 received in 2024. These payments were reported across 2,217 transactions from 71 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Ellenbogen has provided services to 4,942 Medicare beneficiaries, totaling 271,219 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Farmington Hills, MI
- Active Since 01/26/2006
- Last Updated 02/27/2018
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1962472241
Products in Payments
- BOTOX (Biological) $571,047
- INBRIJA (Drug) $122,944
- GOCOVRI (Drug) $120,129
- BOTOX (Drug) $106,543
- AUSTEDO (Drug) $88,659
- Dysport (Drug) $81,688
- APOKYN (Drug) $67,798
- UBRELVY (Drug) $56,173
- DYSPORT (Drug) $53,455
- NOURIANZ (Drug) $41,545
- Xadago (Drug) $38,302
- Horizant (Drug) $27,508
- Austedo XR (Drug) $23,224
- Apokyn (Drug) $20,218
- MYOBLOC (Biological) $18,569
- BOTOX - NEUROLOGY (Drug) $15,399
- Gocovri (Drug) $9,858
- QULIPTA (Drug) $9,856
- NORTHERA (Drug) $9,172
- BOTOX NEURO REHAB (Drug) $8,978
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Farmington Hills
Dr. Richard Trosch, M.d, M.D
Neurology — Payments: $1.3M
Neurology $1.3M
Dr. Martin Belkin, D.o, D.O
Neurology — Payments: $921,158
Neurology $921,158
Dr. Yang Mao-Draayer, Md Phd, MD PHD
Neurology — Payments: $626,761
Neurology $626,761
Dr. Daniel Singer, D.o, D.O
Neurology — Payments: $372,051
Neurology $372,051
Mark Silverman, Do, DO
Neurology — Payments: $368,484
Neurology $368,484
Mark Kachadurian, Do, DO
Neurology — Payments: $359,218
Neurology $359,218